Aspen expects Canada nod for generic targeting Novo's Ozempic by September
Source: SeekingAlpha
2026-03-03 12:09:49 ET
More on Novo Nordisk, Aspen Pharmacare
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable
- Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks
- Novo’s China obesity drug posts positive mid-stage trial results
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
Read the full article on Seeking Alpha
For further details see:
Aspen expects Canada nod for generic targeting Novo’s Ozempic by September
Aspen Pharmacare Holdings Ltd ADR
NASDAQ: APNHY
APNHY Trading
0.0% G/L:
$8.40 Last:
186 Volume:
$8.40 Open:
